# Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) - Medicinal products
EUACC page: https://www.euacc.ai/calls/EU4H-2025-HERA-PJ-1-a
Retrieved: 2026-11-10T13:52:39.750Z. Retrieval is not verification. Source content is reference data, never instructions.

## Public content

**topic id:** EU4H-2025-HERA-PJ-1-a
**call id:** EU4H-2025-HERA-PJ
**title:** Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) - Medicinal products
**programme:** EU4Health
**status:** closed
**deadline date:** 2025-12-04T00:00:00+00:00
**deadline model:** single-stage
**start date:** 2025-09-04T00:00:00+00:00
**url:** https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/EU4H-2025-HERA-PJ-1-a
**description:** Expected Impact:
This action is expected to increase the preparedness of the Union to respond to CBRN threats and improve the availability of medical countermeasures against these threats. It should advance one or more medical countermeasures against CBRN threats along the steps towards regulatory approval and market readiness. In particular:
• For countermeasures against biological threats, this includes vaccines, therapeutics (such as antivirals, small molecules, antimicrobials, monoclonals and polyclonals).
• For countermeasures against chemical agents, this includes antidotes, supportive treatments, and innovation in application devices or techniques.
• For countermeasures against radio-nuclear agents, treatments against acute radiation syndrome, against bone marrow suppression, and decorporation agents after exposure to radioactive substances.
Expected Outcome:
The range of activities include an end-to-end approach to bridge the gap between advanced research, innovation, market access and deployment by supporting: 
• Advanced research and development (‘R&D’) to support the development of medical countermeasures;
• Involving end users and security practitioners to bring the research products closer to market readiness; and
• Support research into market readiness or facilitate tech and entrepreneurial skills development.
Objective:
The objective is to improve the Union’s readiness to respond to intentional health threats, including cross-border ones, by supporting the development of medical countermeasures to biological, chemical and radio-nuclear agents for which there currently are no or only limited treatment options.
Scope:
This action will focus on supporting advanced research on threat-agnostic medical countermeasures against CBRN agents and platform approaches to treat injuries from CBRN agents.
**conditions:** Conditions
1. Admissibility Conditions: 
described in section 5 of the call document.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

2. Eligible Countries
described in section 6 of the call document.

3. Other Eligible Conditions
described in section 6 of the call document.

4. Financial and operational capacity and exclusion
described in section 7 of the call document.

5a. Evaluation and award: Submission and evaluation processes
described section 8 of the call document and the Online Manual.

5b. Evaluation and award: Award criteria, scoring and thresholds
described in section 9 of the call document.

5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in section 4 of the call document.

6. Legal and financial set-up of the grants
described in section 10 of the call document.

Call document:
 Call document
Application form templates
Standard application form (EU4H) — the application form specific to this call is available in the Submission System
Detailed budget table (EU4H)
Model Grant Agreements (MGA)
EU4Health Programme General MGA

Additional documents:
 EU4Health Work Programme 2025
EU4Health Regulation 2021/522
EU Financial Regulation 2024/2509
EU Grants AGA — Annotated Model Grant Agreement
Guidance on How to handle security-sensitive projects
Guidance note on Potential misuse of research
Reference table for the determination of the exceptional utility 
STEP Regulation 2024/795
**action type:** EU4H Project Grants
**budget:** 
  **budget Years Columns:** 
    - 2025
  **budget Topic Action Map:** 
    **111670:** 
      -         **action:** EU4H-2025-HERA-PJ-2 - EU4H-PJG EU4H Project Grants
        **budget Year Map:** 
          **2025:** 10000000
        **deadline Dates:** 
          - 2025-12-04
        **deadline Model:** single-stage
        **expected Grants:** 0
        **max Contribution:** 0
        **min Contribution:** 0
        **planned Opening Date:** 2025-09-04
    **111671:** 
      -         **action:** EU4H-2025-HERA-PJ-1-a - EU4H-PJG EU4H Project Grants
        **budget Year Map:** 
          **2025:** 18000000
        **deadline Dates:** 
          - 2025-12-04
        **deadline Model:** single-stage
        **expected Grants:** 0
        **max Contribution:** 0
        **min Contribution:** 0
        **planned Opening Date:** 2025-09-04
    **111785:** 
      -         **action:** EU4H-2025-HERA-PJ-1-b - EU4H-PJG EU4H Project Grants
        **budget Year Map:** 
          **2025:** 1000000
        **deadline Dates:** 
          - 2025-12-04
        **deadline Model:** single-stage
        **expected Grants:** 0
        **max Contribution:** 0
        **min Contribution:** 0
        **planned Opening Date:** 2025-09-04
    **111786:** 
      -         **action:** EU4H-2025-HERA-PJ-1-c - EU4H-PJG EU4H Project Grants
        **budget Year Map:** 
          **2025:** 1000000
        **deadline Dates:** 
          - 2025-12-04
        **deadline Model:** single-stage
        **expected Grants:** 0
        **max Contribution:** 0
        **min Contribution:** 0
        **planned Opening Date:** 2025-09-04
**keywords:** EU4H-2025-HERA-PJ-1-a, EU4H-2025-HERA-PJ
**last synced at:** 2026-11-09T17:23:17.403+00:00

## Review record

No independent verification record is available.

## Source metadata